Ventricular Pacing Site Selection (V-PASS)

Status Recruiting

Clinical Trial Summary

The purpose of this study is to determine whether there is a relationship between ventricular lead position and the incidence of heart failure and atrial fibrillation in patients with indication for permanent pacemaker stimulation.

Clinical Trial Description

AV-Block of higher degree is the primary indication for pacing therapy for about 20% of pacemaker patients. Pacing systems with only ventricular stimulation (VVI and VDD) have a fraction of about 40% of all pacemakers in Germany. About 50% of the implanted pacemakers in Germany are dual-chamber pacemakers and one half of them is used for treatment of AV blocks.

Picture 1: Fractions of pacing indications in Germany Picture 2: Fractions of used pacing modes in Germany /1/

A lot of studies proved in the past that the pacing site influenced the development of hemodynamics, heart failure (HF) and atrial fibrillation (AF). Unfortunately, the results are not commonly applicable or statistically assured. Due to this, further examinations are required in order to get explicit statements regarding application of alternative, nonapical ventricular lead positioning.

1. Pilotphase It shall be determined whether a randomized positioning of ventricular leads at 2 defined positions (either Group A: Positioning at right ventricular apex or Group B:. Positioning at right ventricular high septum) is feasible. Included patients will already by examined and followed according to protocol. After having proved feasibility of randomized positioning, the data of these patients shall be used for evaluation of the V-PASS study.

2. Study Phase It shall be evaluated how far 2 defined different ventricular lead positions for permanent pacemaker therapy can influence the combined study endpoint mortality and clinically relevant symptoms of heart failure. Further more the development of hemodynamics and the incidence of atrial fibrillation shall be studied. ;

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00292383
Study type	Interventional
Source	Medtronic BRC
Contact	Matthias E Reimers, Dipl. Documentalist
Phone	0049021152930
Email	Matthias.reimers@vitatron.com
Status	Recruiting
Phase	Phase 4
Completion date	December 2008

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT06023784` - The Impact of LBBAP vs RVP on the Incidence of New-onset Atrial Fibrillation in Patients With Atrioventricular Block	N/A
Completed	`NCT01019213` - Acute and Chronic Effect of His-pacing in Consecutive Patients With AV-block	Phase 4
Completed	`NCT04884100` - enHEART - Exploring Full Content of Optical Signals to Enhance Cardiac Arrhythmia Screening	N/A
Recruiting	`NCT05774262` - Pacemaker Implantation Versus Cardioneuroablation for Functional Atrioventricular Block	N/A
Terminated	`NCT04093414` - Left Bundle Area Versus Selective His Bundle Pacing	N/A
Withdrawn	`NCT00559143` - Biventricular Alternative Pacing	Phase 4
Recruiting	`NCT04730921` - Impact of Left Bundle Branch Area Pacing vs. Right Ventricular Pacing in Atrioventricular Block (LEAP-Block)	N/A
Recruiting	`NCT05585411` - PReventive Effect Of Left Bundle Branch Area Pacing Versus righT vEntricular paCing on All Cause deaTh, Heart Failure Progression, and Ventricular dysSYNChrony in Patients With Substantial Ventricular Pacing (PROTECT-SYNC): Multicenter Prospective Randomized Controlled Trial	N/A
Recruiting	`NCT05575557` - Pulmonary Artery Pressure and Right Heart Evaluation for Patients Requiring Physiological Pacing Treatment	N/A
Completed	`NCT00187278` - Biopace Study: Biventricular Pacing for Atrioventricular Block to Prevent Cardiac Desynchronization	N/A
Recruiting	`NCT04595487` - LVSP vs RVP in Patients With AV Conduction Disorders	N/A
Completed	`NCT04269733` - Risk of Pacing-induced Cardiomyopathy
Recruiting	`NCT03851315` - Left Bundle Branch Area Pacing in AVB Patients
Completed	`NCT02282033` - Safety and Performance Study of the Moderato System	N/A
Completed	`NCT01922518` - Impact of Right Ventricular Pacing Determined by Electrocardiography	N/A
Recruiting	`NCT04624763` - Protection of Cardiac Function With Left Bundle Branch Pacing in Patients With Atrioventricular Block	N/A
Completed	`NCT03231826` - Arrhythmias in Post-Myocardial Infarction Patients
Not yet recruiting	`NCT04437901` - COVIDAR - Arrhythmias in COVID-19
Recruiting	`NCT01717469` - Safety and the Effects of Isolated Left Ventricular Pacing in Patients With Bradyarrhythmias	Phase 4
Completed	`NCT02154750` - AV Delay Optimization vs. Intrinsic Conduction in Pacemaker Patients With Long PR Intervals	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.